NewLink Genetics (NLNK) has reported positive data for a phase 2 study, reinforcing the success of the company within the market.

The phase 2 study was completed using the company’s drug indoximod in patients with advanced melanoma, reports Seeking Alpha. The results are particularly impressive given the combination of indoximod and Keytruda, coupled with the improved outcome from previously reported data.

 After recently reported failed results in a phase 2 study in patients with metastatic breast cancer, the results couldn’t have come at a better time for NLNK. During the trial, 51 patients were treated who suffered with metastatic melanoma. Each of the patients was given indoximod together with Keyruda as a combination treatment. It should be noted, that there was an increase in the complete response rate of this type of treatment. The new data proved an increase in the complete response to 20%. The result highlights a better clinical outcome.

However, the results will need to be confirmed in a larger phase 3 study. The company anticipates that this will recruit up to 600 patients, and is predicted to take up until the end of 2018 to fully enroll the trial. As a result, the conclusion from the study won’t be confirmed for some time.